Indies Pharma Jamaica Limited (JMSE:INDIES)
Jamaica
· Delayed Price · Currency is JMD 3.370
-0.180 (-5.07%)
At close: Mar 12, 2025
Indies Pharma Jamaica Income Statement
Financials in millions JMD. Fiscal year is November - October.
Millions JMD. Fiscal year is Nov - Oct.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jan '25 Jan 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | Oct '20 Oct 31, 2020 | 2016 - 2019 |
| Revenue | 1,215 | 1,159 | 1,055 | 937.28 | 846.83 | 765.95 | Upgrade
|
| Revenue Growth (YoY) | 13.68% | 9.81% | 12.61% | 10.68% | 10.56% | 5.00% | Upgrade
|
| Cost of Revenue | 492.11 | 465.82 | 417.41 | 323.44 | 329.81 | 254.32 | Upgrade
|
| Gross Profit | 723.31 | 693.15 | 638.05 | 613.84 | 517.02 | 511.62 | Upgrade
|
| Selling, General & Admin | 346.66 | 354.55 | 308.57 | 273.53 | 244.65 | 243.65 | Upgrade
|
| Other Operating Expenses | 16.68 | -6.41 | -4.23 | 1.15 | 1.5 | -0.72 | Upgrade
|
| Operating Expenses | 425.2 | 410.01 | 367.82 | 332.13 | 299.61 | 294.42 | Upgrade
|
| Operating Income | 298.11 | 283.15 | 270.24 | 281.71 | 217.41 | 217.2 | Upgrade
|
| Interest Expense | -65.2 | -64.46 | -66.78 | -60.48 | -68.96 | -9.78 | Upgrade
|
| Interest & Investment Income | 1.6 | 1.6 | 1.46 | 0.95 | 4.84 | 0.52 | Upgrade
|
| Currency Exchange Gain (Loss) | 7.71 | 8.78 | 1.86 | -1.75 | 14.76 | 4.3 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.95 | -2.95 | -3.29 | -2.22 | -2.59 | -3.46 | Upgrade
|
| EBT Excluding Unusual Items | 239.29 | 226.12 | 203.48 | 218.21 | 165.47 | 208.79 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.55 | 1.55 | 3.07 | 1.88 | 2.4 | - | Upgrade
|
| Pretax Income | 264.94 | 251.77 | 217.63 | 220.79 | 167.87 | 209.38 | Upgrade
|
| Income Tax Expense | 1.46 | - | - | - | - | 2.03 | Upgrade
|
| Net Income | 263.47 | 251.77 | 217.63 | 220.79 | 167.87 | 207.35 | Upgrade
|
| Net Income to Common | 263.47 | 251.77 | 217.63 | 220.79 | 167.87 | 207.35 | Upgrade
|
| Net Income Growth | 19.17% | 15.69% | -1.43% | 31.53% | -19.04% | 58.33% | Upgrade
|
| Shares Outstanding (Basic) | 1,331 | 1,333 | 1,333 | 1,333 | 1,333 | 1,333 | Upgrade
|
| Shares Outstanding (Diluted) | 1,331 | 1,333 | 1,333 | 1,333 | 1,333 | 1,333 | Upgrade
|
| Shares Change (YoY) | -0.42% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 0.20 | 0.19 | 0.16 | 0.17 | 0.13 | 0.16 | Upgrade
|
| EPS (Diluted) | 0.20 | 0.19 | 0.16 | 0.17 | 0.13 | 0.16 | Upgrade
|
| EPS Growth | 19.67% | 15.69% | -1.43% | 31.53% | -19.04% | 58.33% | Upgrade
|
| Free Cash Flow | 370.02 | 241.13 | 265.45 | 288.85 | 325.76 | -109.52 | Upgrade
|
| Free Cash Flow Per Share | 0.28 | 0.18 | 0.20 | 0.22 | 0.24 | -0.08 | Upgrade
|
| Dividend Per Share | 0.110 | 0.110 | 0.110 | 0.113 | 0.110 | 0.140 | Upgrade
|
| Dividend Growth | - | - | -2.66% | 2.73% | -21.43% | - | Upgrade
|
| Gross Margin | 59.51% | 59.81% | 60.45% | 65.49% | 61.05% | 66.80% | Upgrade
|
| Operating Margin | 24.53% | 24.43% | 25.60% | 30.06% | 25.67% | 28.36% | Upgrade
|
| Profit Margin | 21.68% | 21.72% | 20.62% | 23.56% | 19.82% | 27.07% | Upgrade
|
| Free Cash Flow Margin | 30.44% | 20.80% | 25.15% | 30.82% | 38.47% | -14.30% | Upgrade
|
| EBITDA | 317.61 | 303.32 | 289.13 | 300.95 | 233.54 | 228.5 | Upgrade
|
| EBITDA Margin | 26.13% | 26.17% | 27.39% | 32.11% | 27.58% | 29.83% | Upgrade
|
| D&A For EBITDA | 19.5 | 20.17 | 18.9 | 19.24 | 16.13 | 11.3 | Upgrade
|
| EBIT | 298.11 | 283.15 | 270.24 | 281.71 | 217.41 | 217.2 | Upgrade
|
| EBIT Margin | 24.53% | 24.43% | 25.60% | 30.06% | 25.67% | 28.36% | Upgrade
|
| Effective Tax Rate | 0.55% | - | - | - | - | 0.97% | Upgrade
|
| Advertising Expenses | - | 10.72 | 5.27 | 4.98 | 6.5 | 4.74 | Upgrade
|
Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.